Drug Trial Radar · NCT06967805
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
168
Actual
Start
May 5, 2025
Primary completion
Aug 2027
Study completion Aug 2027
Sponsor
- Lead sponsor
- Mediar TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- May 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
MTX-463Biological
MTX-463 is an immunoglobin G1 (IgG1) monoclonal antibody directed against WNT-inducible signaling pathway protein 1 (WISP1). WISP1 (aka CCN-4) is a matricellular protein that appears to be upregulated locally in response to certain chronic diseases, including IPF, and malignancies.
PlaceboOther
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the effect of MTX-463 on the change from Baseline in forced vital capacity (FVC)Time frame: 24 Weeks
Locations
59 sites in 11 countries. Site status is shown where the registry gives one.
WISPer Site in Birmingham, AL
Birmingham, Alabama
WISPer site in Phoenix, AZ
Phoenix, Arizona
WISPer site in Newport Beach, CA
Newport Beach, California
WISPer Site in Palm Springs, CA
Palm Springs, California
WISPer Site in Denver, CO
Denver, Colorado
WISPer site in Loxahatchee, FL
Loxahatchee Groves, Florida
WISPer Site in Atlanta, GA
Atlanta, Georgia
WISPer site in Champaign, IL
Champaign, Illinois
WISPer site in Kansas City, KS
Kansas City, Kansas
WISPer site in Shreveport, LA
Shreveport, Louisiana
WISPer Site in Baltimore, MD
Baltimore, Maryland
WISPer Site in Boston, MA
Boston, Massachusetts
WISPer Site in Ann Arbor, MI
Ann Arbor, Michigan
WISPer site in New York, NY
New York, New York
WISPer Site in Durham, NC
Durham, North Carolina
WISPer site in Greensboro, NC
Greensboro, North Carolina
WISPer site in Oklahoma City, OK
Oklahoma City, Oklahoma
WISPer Site in Pittsburgh, PA
Pittsburgh, Pennsylvania
WISPer Site in Charleston, SC
Charleston, South Carolina
WISPer site in Dallas, TX
Dallas, Texas
WISPer Site in Salt Lake City, UT
Salt Lake City, Utah
WISPer Site in Milwaukee, WI
Milwaukee, Wisconsin
WISPer Site in Buenos Aires, Argentina
Buenos Aires, Argentina
WISPer Site in Buenos Aires, Argentina
Buenos Aires, Argentina
WISPer Site in Cordoba, Argentina
Córdoba, Argentina
WISPer Site in Mendoza, Argentina
Mendoza, Argentina
WISPer Site in San Miguel De Tucumán, Argentina
San Miguel de Tucumán, Argentina
WISPer site in Melbourne, Australia
Melbourne, Australia
WISPer site in Midland, Australia
Midland, Australia
WISPer site in Westmead, Australia
Westmead, Australia
WISPer Site in Brussels, Belgium
Brussels, Belgium
WISPer Site in Edegem, Belgium
Edegem, Belgium
WISPer Site in Belo Horizonte, Brazil
Belo Horizonte, Brazil
WISPer Site in Curitiba, Brazil
Curitiba, Brazil
WISPer Site in Passo Fundo, Brazil
Passo Fundo, Brazil
WISPer Site in Porto Alegre, Brazil
Porto Alegre, Brazil
WISPer Site in São Bernardo Do Campo, Brazil
São Bernardo do Campo, Brazil
WISPer Site in Sao Paulo, Brazil
São Paulo, Brazil
WISPer Site in Calgary, Alberta
Calgary, Alberta, Canada
WISPer site in Ajax, ON
Ajax, Ontario, Canada
Showing 40 of 59 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.